02606nas a2200493 4500000000100000008004100001260003700042653001500079653001000094653000900104653001100113653001100124653001200135653000900147653002300156653001600179653002100195653002800216653002700244653002700271653001700298653003000315653001700345653002100362653001600383100001400399700001600413700001300429700001800442700001600460700001200476700001300488700001200501700001200513700001500525700001600540245023200556856005100788300001100839490000700850050001600857520122500873022001402098 2012 d c2012 Jun bLEPRA Health in Action 10 aAdolescent 10 aAdult 10 aAged 10 aFemale 10 aHumans 10 aleprosy 10 aMale 10 aMethylprednisolone 10 aMiddle Aged 10 aMuscle, Skeletal 10 aNervous System Diseases 10 aNeurologic Examination 10 aNeuroprotective Agents 10 aPrednisolone 10 aSeverity of Illness Index 10 aTibial Nerve 10 aTrigeminal Nerve 10 aYoung Adult 1 aWalker SL 1 aNicholls PG 1 aDhakal S 1 aHawksworth RA 1 aMacdonald M 1 aMahat K 1 aRuchal S 1 aHamal S 1 aHagge D 1 aNeupane KD 1 aLockwood DN 00 aA comparison of the change in clinical severity scale score and a retrospective physician assessment of neurological outcome in individuals with leprosy associated nerve function impairment after treatment with corticosteroids. uhttps://leprosyreview.org/article/83/2/12-1685 a154-63 0 v83 aWALKER 2012 3 aOBJECTIVES: To determine whether the measured change in score of a validated clinical severity scale reflected physician assessed improvement in individuals who had received corticosteroid therapy for leprosy associated nerve damage.
DESIGN: Patients with nerve function impairment who participated in a randomised controlled trial of corticosteroids were classified into two groups using a retrospectively determined physician assessment of improvement. One group consisted of patients who had recovered or improved the other of patients who were unchanged or had deteriorated. The change in the clinical severity scale scores of these two groups was compared.
RESULTS: The change in the clinical severity scale scores of the 34 eligible individuals in the two groups were significantly different (P = 0.003). Individuals in the group who recovered or improved had a greater change in severity score than those whose nerve function was unchanged or deteriorated.
CONCLUSION: The scale for measuring the severity of leprosy Type 1 reactions (T1Rs) and/or nerve function impairment reflects the clinical improvement of individuals with leprosy associated nerve damage.
a0305-7518